anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses the method that multiple biological activities ingredient in a kind of soft-shelled turtle integrates extraction, including step：S1. soft-shelled turtle particle liquid adds in compound protease A enzymolysis；S2. the broken bone of filtering Soft-shelled Turtle Enzymatic Hydrolysates separation soft-shelled turtle and turtle product liquid, centrifuge to obtain turtle water-phase product and turtle oil-phase product；S3. turtle water-phase product carries out deodorant, decoloration, refined filtration, concentration, dry the oligomeric Gly-His-Lys of turtle；S4. the broken bone liquid of soft-shelled turtle through boiling, filter bone slag and broken bone product liquid, centrifuge to obtain soft-shelled turtle bone protein liquid and soft-shelled turtle bone oil-phase product；S5. soft-shelled turtle bone protein liquid adds in compound protease B and digests to obtain soft-shelled turtle bone protein enzymolysis product；S6. soft-shelled turtle bone protein enzymolysis product is through deodorant, decoloration, refined filtration, concentration, dry the oligomeric Gly-His-Lys of soft-shelled turtle bone protein；S7. bone Slag treatment obtains soft-shelled turtle carapace powder；S8. turtle oil-phase product and soft-shelled turtle bone oil-phase product mix to obtain Turtle Oil.The present invention can make full use of soft-shelled turtle resource, avoid the wasting of resources.
FIELD: biotechnology, molecular biology, genetic engineering, pharmacy. SUBSTANCE: invention relates to method for preparing and preparation of human recombinant gamma-interferon. Constructed recombinant plasmid pGIF 315 comprises promoters providing high constitutive expression of gene in cells E. coli encoding gamma-interferon with size 144 pairs of nitrogen bases with molecular mass 16.9 kDa. Method for preparing interferon involves culturing strain E. coli transformed with plasmid pGIF 315 in nutrient medium without deficiency of any components or addition of any inducing agents for synthesis of gamma-interferon. After lysis of cells precipitate is washed out with 1-3 M urea solutions and dissolved in 6-8 M urea solution. Prepared solution is applied on cation-exchange sorbent and elution with urea-free buffer is carried out that provides renaturation of gamma-interferon. Preparation of human recombinant gamma-interferon comprises additionally biologically inert low-molecular filling agent and salt. Invention provides creation of plasmid resulting to high yield of gamma-interferon. Also, invention relates to creation of medicinal preparations of human gamma-interferon and recombinant plasmid DNA encoding its synthesis. EFFECT: improved preparing method. 6 cl, 1 tbl
The present invention generally relates to systems and methods suitable for high-level protein production. While one or more elements of the present invention are derived from an alphavirus, the present invention does not require propagation of virus particles. In particular, a system comprising two separate RNA molecules is foreseen, each comprising a nucleotide sequence derived from an alphavirus: one RNA molecule comprises a RNA construct for expressing alphavirus replicase, and one RNA molecule comprises a RNA replicon that can be replicated by the replicase in trans. The RNA construct for expressing alphavirus replicase comprises a 5'-cap. It was surprisingly found that the 5'-cap is suitable for efficiently driving expression of a transgene from the replicon in trans. The system of the present invention enables expression of a protein of interest in a cell or organism, but is not associated with undesired virus-particle formation. Therefore, the present invention is suitable for efficiently and safely producing a protein of interest, e.g. a therapeutic protein or an antigenic protein, such as a vaccine, in a target organism. Respective methods of protein production in vitro and in vivo as well as medical uses are provided herein. The present invention also provides DNA encoding the RNA molecules of the invention, and cells comprising the RNA molecules of the invention.
A pharmaceutical composition comprising 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano[3,2-g]quinoline-2,8-dicarboxylic acid or a pharmaceutically acceptable salt thereof, a pressurized or liquefied gas propellant, and a flavoring agent and/or a sweetening agent is useful in the treatment of reversible obstructive airways disease. The composition preferably contains nedocromil sodium as active ingredient. Flavoring agents which may be used include menthol and peppermint oil. Sweetening agents which may be used include sugar, aspartame, cyclamates and saccharin or salts thereof. The composition preferably includes both a flavoring agent and a sweetening agent. Any conventional aerosol propellant may be used, e.g. a mixture of Propellant 12 and Propellant 114, and the composition is preferably packaged in a conventional pressurized aerosol canister fitted with a dispensing metering valve.
In this arm, screening for GDM will follow standard practice. 80 women diagnosed with GDM in 10 randomly selected primary health care facilities and who consent to participate will be followed up.
The whole exercise lasts for 12 months, consisted of 6-month supervised exercise and 6-month maintenance period. It is moderate -intensity exercise (60-80% Maximum heart rate), each time last for 30 mins (plus 10-minutes for warm-up and cool-down), 3-4 times a week, for the first six months, which will be supervised in person by physical educators and/or physical professionals. In the maintenance period, participants are asked to exercise at the same intensity and frequency, but will not be supervised in person by physical educators/professionals. They will receive reminder on a weekly basis and their physical activities be recorded by accelerometer. Types of exercise will be chosen according to individual school's facility and feasibility, including jogging, fast walking, badminton, running, football etc.
Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period. Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
Keratoconus is a degenerative pathology of the cornea, which tends to progress. It comes along with central and paracentral thinning of the cornea as well as with an apical protrusion of the cornea. Keratoconus leads to vision loss. This pathology is diagnosed by using CE certified OCT technology in order to map the topography of the cornea. This process constitutes a really important step in the line of management of the keratoconus. MS39 and Pentacam are used for detection. Retrospectively, data will be investigated, in order to see if these measurement devices deliver comparable results. In the future, these measurement devices could be interchangeable in usage.
PURPOSE:To obtain a liquid agent of Clostridium butyricum causing no germination of its spore cell even in the presence of water and capable of readily administering by keeping a liquid containing Clostridium butyricum to acidity or including phenylalanine and/or asparagine in the liquid. CONSTITUTION:A liquid agent of Clostridium butyricum consisting mainly of Clostridium butyricum and kept to acidity (preferably pH2-5, especially 4-5) in a normal state or a liquid agent of Clostridium butyricum consisting mainly of Clostridium butyricum and containing >=0.1% phenylalanine or asparagine. The Clostridium butyricum includes preferably e.g. Clostridium butyricum NIP1006 (FERM P-11868), NIP1015 (FERM P-11869), NIP1017 (FERM P-11870), especially preferably Clostridium butyricum Miyairi 588 (FERM P-2789). This liquid agent is used for improving symptoms due to abnormality of intestinal bacterial flora of human and animals. The liquid agent is used as a syrup, limonades, a drink agent, a soft drink water, a liquid food, a semi-fluid food, ice cream, etc.
Sitosterol and its glycosides of improved bioavailability are in the form of microemulsions using lecithin as the carrier. Pref. the microemulsions contain isopropylmyristate as emulsifier and isopropanol as co-emulsifier. The microemulsions consists of 21-23% lecithin, 15-16% isopropanol and 7.0-7.5% isopropanolmyristate in water as the dispersant. USE/ADVANTAGE - Beta-sitosterol is practically non-toxic and has antipyretic, cholesterol-reducing and antiproliferative properties, and does not accumulate anywhere in the body, but as a result of its low water solubility is not resorbed well from the gastro-intestinal tract. When sitosterol and its glycosides are in the form of microemulsions using lecithin as carrier, the bioavailabilty is much better. The microemulsions are semi-solid, transparent and can be stored for long periods without changing. When given p.o. to rats, the resorption of beta-sitosterol from a suitable microemulsion was 24%, while from a suspension in distilled water, the resorption was 18%
PURPOSE:To obtain the title material having adequate therapeutic effects with the liquid drug sustainedly releasable over a long period of time, by covering a ceramic porous part with a second ceramic porous part with its pore size and porosity smaller than those of the former part. CONSTITUTION:The objective material 1 impregnated with a specified liquid drug in advance and to sustainedly release the drug in such a slate as to be embedded near the affected sites in vivo, can be obtained by covering the first porous part (esp. a spherical porous form 2 of high porosity) made of a ceramic member (e.g. highly biocompatible beta-calcium phosphate) with the second porous form (esp. a porous form 3 of low porosity) made of a second ceramic member with its pore size and/or porosity smaller than those of the first porous part. Change in the properties of the first and second porous parts can control their liquid drug impregnation degrees and sustained release capabilities. The present material can be put to long-term therapeutic use for affected sites by sustainedly releasing a liquid drug such as antibiolic or carcinostatic.
According to one embodiment, a method, computer system, and computer program product for digital twin carrier simulation is provided. The embodiment may include identifying an occurrence of a contamination event. The embodiment may also include generating a digital twin of an area within a preconfigured distance of the contamination event. The embodiment may further include identifying one or more modes of spread for a contaminant released during the contamination event. The embodiment may also include performing a digital twin simulation of the area using the generated digital twin and the one or more identified modes of spread. The embodiment may further include calculating a contaminant propagation pattern based on the digital twin simulation.
A method for produce sanitation using bacteriophages is disclosed. According to one embodiment of the present invention, the method includes the steps of (1) providing at least one bacteriophage; and (2) applying the bacteriophage to the produce. The produce may include fruits and vegetables. The produce may be freshly-cut produce, damaged produce, diseased produce, or contaminated produce. The produce may be sprayed with bacteriophage, washed with bacteriophage, immersed in a liquid containing bacteriophage, etc. The bacteriophage may be applied once, periodically or continuously. In one embodiment, chemical sanitizers may also be applied to the produce.
Diabetic ketoacidosis (DKA) is a life-threatening complication of diabetes mellitus. Sodium-glucose co-transport inhibitors (SGLT-2i), a treatment for type 2 diabetes, have demonstrated a survival benefit in patients with heart failure with reduced ejection fraction (HFrEF). Many patients with HFrEF have been started on SGLT-2i and sometimes transitioned off insulin due to improved glycaemic control. SGLT-2i have demonstrated an association with DKA. Here, we present a case of simultaneous cardiogenic shock and DKA in the setting of recent transition from insulin to an SGLT-2i. DKA in conjunction with decompensated heart failure is a combination that will likely occur more frequently as SGLT-2i use becomes more widespread in patients with HFrEF, and its identification and management require special considerations. Volume status, potassium management and recognition of DKA in these patients must be approached differently than in other cases of DKA.
OBJECTIVE: Lumbar degenerative diseases (LDDs) with huge herniation in the left lateral recess or central canal present challenges for oblique lateral lumbar interbody fusion (OLIF) or endoscope-assisted OLIF procedures. Currently, minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) is the primary approach for this issue. This study aims to provide a standardized technical description of the anterior lumbar discectomy and fusion (ALDF) and evaluate the medium-term clinical effectiveness of both ALDF and MIS-TLIF techniques.
METHODS: A retrospective review was performed on LDDs who underwent ALDF and MIS-TLIF surgery from January 2018 to January 2020. The evaluation encompassed various clinical outcomes, such as the visual analogue scale (VAS) scores for back pain and leg pain (VAS-back, VAS-leg), the Oswestry disability index (ODI), the 36-item short-form health survey mental component summary (SF-36 MCS), and the physical component summary (SF-36 PCS). Additionally, radiological parameters, including disc height (DH), segmental disk angle (SDA), lumbar lordosis (LL), and cross-sectional area (CSA), were assessed. Data including radiculopathy, estimated blood loss, operation time, time of getting out of bed, fusion rate, and complications were recorded. Student's independent samples t test and Pearson's chi-square test were used to compare the differences between groups.
RESULTS: In total, 47 patients were treated by ALDF and 48 patients were treated by MIS-TLIF. The ALDF group exhibited statistically significant lower estimated blood loss and earlier time of getting out of bed compared to the MIS-TLIF group (p < 0.05). The ALDF group demonstrated lower VAS-back scores and a higher remission rate of low back pain 3 years after the surgery (p < 0.05). During the entire follow-up period, the ALDF group exhibited higher increases in DH and SDA compared to the MIS-TLIF group (p < 0.05). At 6 months, the fusion rate in the ALDF group was significantly higher than in the MIS-TLIF group (p < 0.05). The comparison revealed no statistically significant differences in complication rates between the two groups (p > 0.05).
CONCLUSION: The ALDF could be considered as a viable surgical alternative for the treatment of LDDs that necessitate ventral neural direct decompression. ALDF exhibited favorable medium-term outcomes in patients with LDDs, displaying advantages in facilitating expedited recovery, enhancing radiographic outcomes, and elevating the remission rate of low back pain. Although ALDF presents slightly higher complication rates compared to MIS-TLIF, it does not adversely affect clinical outcomes.
### 

Adverse Events from Ankylosing Spondylitis Studies: A total of 378 patients were treated with CELEBREX in placebo- and active-controlled AS studies. Doses up to 400 mg once daily were studied. The types of adverse events reported in the AS studies were similar to those reported in the OA/RAstudies.

### 

Adverse Events from Analgesia and Dysmenorrhea Studies: Approximately 1,700 patients were treated with CELEBREX in analgesia and dysmenorrhea studies. All patients in post-oral surgery pain studies received a single dose of study medication. Doses up to 600 mg/day of CELEBREX were studied in primary dysmenorrhea and post-orthopedic surgery pain studies. The types of adverse events in the analgesia and dysmenorrhea studies were similar to those reported in arthritis studies. The only additional adverse event reported was post-dental extraction alveolar osteitis (dry socket) in the post-oral surgery pain studies.
PCT No. PCT/SE94/00595 Sec. 371 Date Dec. 4, 1995 Sec. 102(e) Date Dec. 4, 1995 PCT Filed Jun. 16, 1994 PCT Pub. No. WO95/00152 PCT Pub. Date Jan. 5, 1995The present invention relates to pharmaceutical compositions containing heparin or heparin fragments or their derivatives in combination with one or more glycerol esters of at least one fatty acid as single absorption enhancer. The compositions are useful for oral administration, for administration through mucous membranes or for transdermal administration. The compositions will when necessary contain further physiologically acceptable additives, such as diluents and/or carriers, suitable for the adaptation to oral, buccal, rectal, sublingual, nasal, subcutaneous or transdermal administration. The composition according to the invention provide excellent absorption and bioavailability without employing additional enhancers or promoters.
Systems and methods for monitoring one or more addictive activities by an addict. A system includes at least at least one biosensor, a processor, and a communication system. The at least one biosensor measures physiological data from the addict. The processor generates a notification when the addict has participated in the one or more addictive activities based on the physiological data. The communication system sends the notification to one or more devices of the addict and/or of the members of an addiction support network of the addict to notify that the addict has participated in the addictive activities. The system uses geographical location or proximity data to notify the addict that the addict has entered a defined dangerous geographical zone or exited a defined safe geographical zone. The system includes a mobile system that automatically detects if the mobile system is being worn by the addict.
An interactive multi-purpose interactive cognitive platform is provided that uses image-based interactivities and may use enriched visual stimuli for diagnoses, treatment, and to evaluate and assess the progress and/or treatment of cognitive diseases and/or conditions with cognitive impacts. The platform may be used for performance enhancement training. The platform may include a graphical user interface. The platform is designed to cooperatively engage multiple cognitive domains using interactivities-embedded assessments. The images and image sets may involve the application of Gestalt principles for assessments and may be personalized address individual user preferences. The multi-purpose interactive cognitive platform may be used to produce diagnostics and/or treatment plans for specific cognitive conditions and diseases with a cognitive component. The multi-purpose interactive cognitive platform may be used for gaming, stress reduction, mindfulness, skills development, training, and/or performance enhancement for those without cognitive problems and/or for those interested in maintaining their cognitive health.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely, to efferent therapy, and can be applied in treatment of patients with hepatic failure after performed cardio-surgical operation. For this purpose realised is veno-venous hemofiltration with application of standard bicarbonate solution. If clinical and laboratory signs of hepatic failure increase following sessions of hemofiltration are carried out during 5-8 hours with application of dialytic solution based on standard bicarbonate solution with 2% content of albumen. After session of hemofiltration with such solution, laboratory control of basic functional hepatic indices is performed. In case of necessity additional sessions with application of dialytic solution which contains 2% albumen are carried out. ^ EFFECT: method makes it possible to increase efficiency of small-flow veno-venous hemofiltration due to increase of clearance of endotoxins, associated with blood plasma proteins. ^ 2 cl, 2 ex
PROBLEM TO BE SOLVED: To obtain a surfactant which shows a high safety to a human body, high biodegradability, an acid resisting power, cosmetically whitening and moisture retaining effects and lessens the dependence upon temperature. SOLUTION: An aqueous sericin solution is extracted from a sericin contained in a cocoon or silk with water and its pH value is adjusted to about 3-5 by an organic acid or an inorganic acid. Further, an organic flocculating agent or an inorganic flocculating agent is added to deposit the sericin, which is, in turn, filtered and dried into a solid sericin. The sericin thus obtained is odorless and tasteless and can be used for mayonnaise or the like as food, for cream or the like as a cosmetic and for a hand soap or the like as a detergent, all being in the form of a surfactant. This surfactant is free from functional deterioration at a low temperature and denaturation and coagulation at a high temperature, so that the range of temperatures for applications is wide.  The sericin itself possesses moisture retaining and cosmetically whitening effects, and further, suppresses the oxidation of oils/fats in an emulsion through anti-oxidation action to maintain the oils/fats in a good condition for a long time. The sericin is a natural product, hence a high safety to the human body and environments is secured.
INTRODUCTION: Pediatric ankle injuries are a common presentation in the emergency department (ED). A quarter of pediatric ankle fractures show no radiographic evidence of a fracture. Physicians often correlate non-weight bearing and tenderness with an occult fracture. We present this study to predict the probability of an occult fracture using radiographic soft-tissue swelling on initial ED radiographs.
METHODS: This is a retrospective study at a Level 1 pediatric trauma center from 2021 to 22. Soft-tissue swelling between the lateral malleolus and skin was measured on radiographs, and weight-bearing status was documented. Statistical analysis was conducted using Stata software.
DISCUSSION: The study period involved 32 patients with an occult fracture, with 8 (25%) diagnosed with a fracture on follow-up radiographs. The probability of an occult fracture was calculated as a function of the ankle swelling in millimeters (mm) using a computer-generated predictive model. False-negative and false-positive rates were plotted as a function of the degree of ankle swelling.
CONCLUSION: Magnitude of ankle soft-tissue swelling as measured on initial ED radiographs is predictive of an occult fracture. Although weight-bearing status was not a sign of occult fracture, it improves the predictive accuracy of soft-tissue swelling.
FIELD: medicine. SUBSTANCE: method involves performing gastrotomy in performing laparotomy. Ethanol solution is infused one hour before making laparotomy. PH value is measured with probe introduced through gastrotomy opening. In particular cases, 15% ethanol solution is applied as stimulation agent in the amount of at least 200 g. EFFECT: enhanced reliability and acceleration of examination; excluded undesirable side effects. 2 cl
PURPOSE:To obtain the porous body of calcium phosphate compd. which has both proper physical strength as the filler (prosthesis) of bones and teeth and porosity capable of growing the bony tissue therein by kneading calcium phosphate compd. and nonvolatile organic liquid and thereafter molding this kneaded material and sintering the molded material. CONSTITUTION:Calcium phosphate compd. and nonvolatile organic liquid are kneaded and thereafter this kneaded material is molded and the molded body is sintered. As calcium phosphate compd., hydroxyapatite and tricalcium phosphate are utilized and besides calcium hydrogenphosphate, calcium dihydrogenphosphate and compds. contg. several impure components may be utilized. As the nonvolatile organic liquid, the aqueous liquid material of methyl cellulose, polyethylene glycol or PVA are preferably utilized. A porous body having required porosity (about 20-60%) especially available as an implanting material of bones and a dental root is obtained by properly selecting the amount of the organic liquid. Sintering is preferably performed at 600-1300 deg.C in the oxidative atmosphere such as air.